Eisai invests $15m in C₂N Diagnostics to advance Alzheimer’s disease diagnostics
In a significant move for the field of brain health diagnostics, C₂N Diagnostics, LLC, a pioneer in developing advanced diagnostic solutions for Alzheimer’s disease, has secured an investment of up to $15 million from Eisai Inc., a globally recognized human health care company. This strategic partnership underscores a shared commitment between the two firms to revolutionize the diagnosis and management of Alzheimer’s disease through innovative blood tests, notably C₂N’s Precivity tests, designed for patients experiencing cognitive impairment.
The Precivity tests by C₂N Diagnostics represent a groundbreaking approach in the Alzheimer’s disease diagnostic landscape. Aimed at assisting healthcare providers in identifying Alzheimer’s disease pathology, these tests are crucial in guiding medical management and treatment decisions. The investment from Eisai Inc. is set to propel C₂N’s mission to enhance the availability, accessibility, and utilization of high-performance blood biomarker tests for early Alzheimer’s diagnosis across the United States.
Dr. Joel Braunstein, CEO of C₂N Diagnostics, expressed gratitude towards Eisai for their thorough evaluation and support, stating, “With this financing, we’re building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer’s disease through early detection and treatment and, ultimately, prevention.” Dr. Braunstein highlighted the transformative potential of this collaboration in improving clinical care standards for Alzheimer’s patients. The integration of blood biomarkers, closely correlated with gold-standard measures such as PET scans, is anticipated to significantly enhance patient access to safe and effective treatments.
Keisuke Naito, Global Alzheimer’s Disease Officer and Senior Vice President at Eisai, echoed the importance of advancing blood-based diagnostics, citing the limitations and expenses associated with traditional PET and CSF tests. Eisai’s vision is to cultivate the dementia ecosystem, making diagnostic tools more affordable and minimally invasive, thereby ensuring broad access to Alzheimer’s disease management.
The partnership between C₂N and Eisai began in 2022, with both entities focusing on raising awareness and developing real-world evidence to advocate for the use of blood-based assays in the care of individuals with cognitive impairments outside of clinical trials. This collaboration marks a pivotal step in making advanced diagnostics more accessible and could potentially shift the paradigm in the early detection and treatment of Alzheimer’s disease.
The strategic investment by Eisai Inc. in C₂N Diagnostics is a significant milestone in the battle against Alzheimer’s disease. By focusing on the development and deployment of advanced blood tests for early diagnosis, this partnership paves the way for a future where Alzheimer’s can be detected and managed more effectively. The emphasis on blood biomarkers as a minimally invasive and cost-effective alternative to traditional diagnostic methods represents a significant advancement in the field, offering hope for earlier treatment interventions and, ultimately, improved patient outcomes.